Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine

Journal of Molecular and Cellular Cardiology

Volumn 31, Issue 1, 1999, Pages 275-281

  Mason, R Preston ^a   Walter, Mary F ^a   Trumbore, Mark W ^a,b   Olmstead Jr , Edwin G ^a,c   Mason, Pamela E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GORDON COLLEGE   (United States)

Author keywords

Calcium channels; Calorimetry; Lipid peroxidation; Membranes

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; LIPID PEROXIDE; POLYUNSATURATED FATTY ACID; VERAPAMIL;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG POTENCY; ENTHALPY; MEMBRANE DAMAGE; MEMBRANE VESICLE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THERMODYNAMICS;

EID: 0033051979     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0867     Document Type: Article

References (21)

1. Bauerle HD, Seelig J, 1991. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location. Biochemistry 30: 7203-7211.
2. Burges RA, Gardiner DG, Gwilt M, Higgins AJ, Blackburn KJ, Campbell SF, Cross PE, Stubbs JK, 1987. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: Evidence of voltage modulation of vascular dihydropyridine receptors. J Cardiovasc Pharmacol 9: 110-119.
3. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, Mcmurray J, 1992. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl-and nonsulfhydryl-containing ACE inhibitors. J CarDiovasc Pharmacol 19: 330-340.
4. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E, 1996. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 131: 146-152.
5. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G, 1989. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 30: 627-630.
6. Fernandes AC, Filipe PM, Freitas JP, Manso CF, 1996. Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification. Free Radic Biol Med 20: 507-514.
7. Freedman AM, Cassidy MM, Weglicki WB, 1991. Captopril protects against myocardial injury induced by magnesium deficiency. Hypertension 18: 142-147.
8. Henry PD, 1991. Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 18: S6-S10.
9. Janero DR, Burghardt B, Lopez R, 1988. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 37: 4197-4203.
10. Mak IT, Boehme P, Weglicki WB, 1992. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells: Correlation of protection with preservation of glutathione levels. Circ Res 70: 1099-1103.
11. Mak IT, Weglicki WB, 1990. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1452.
12. Mason RP, 1993. Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity. Biochem Pharmacol 45: 2173-2183.
13. Mason RP, 1998. Cytoprotective properties of a long-acting calcium channel blocker: New mechanism of action. Am J Hypertens 11: A245.
14. Mason RP, Campbell SF, Wang SD, Herbette LG, 1989. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 36: 634-640.
15. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 41: 315-321.
16. Mason RP, Trumbore MW, 1996. Differential membrane interactions of calcium channel blockers. Implications for antioxidant activity. Biochem Pharmacol 51: 653-660.
17. Mclean LR, Hagaman KA, 1992. Effect of lipid physical state on the rate of peroxidation of liposomes. Free Radic Biol Med 12: 113-119.
18. Narula J, Haider N, Virmani R, Disalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA, 1996. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189.
19. Ondrias K, Misik V, Gergel D, Stasko A, 1989. Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. Biochim Biophys Acta 1003: 238-245.
20. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, Demets DL, 1996. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group. N Engl J Med 335: 1107-1114.
21. Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP, 1997. Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 62 (Suppl. 2): S55-S66.